Kelly Blackburn

Kelly Blackburn has more than 25 years of experience in clinical development operations, most recently as Senior Vice President, Clinical Affairs at aTyr Pharma and as Vice President, Clinical Development Operations at Vertex. Of note, she held the senior global clinical operational responsibility for three major novel therapeutics: Kalydeco® for the treatment of cystic fibrosis, Incivek® for hepatitis C, and Velcade® for multiple myeloma.

Kelly is an active board member of the Hildebrand Family Self-Help Center, Cambridge MA; and long-standing long-standing volunteer case reviewer and emergency foster care mother for the Department of Children and Families in Massachusetts. She has an MHA degree from Quinnipiac University and a BS degree in biochemistry from the University of New Hampshire.